Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aurinia Pharm Ord (AUPH)

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,286,096
  • Shares Outstanding, K 142,110
  • Annual Sales, $ 45,610 K
  • Annual Income, $ -180,970 K
  • 60-Month Beta 0.87
  • Price/Sales 9.97
  • Price/Cash Flow N/A
  • Price/Book 2.75
Trade AUPH with:

Options Overview Details

View History
  • Implied Volatility 119.04% ( -3.97%)
  • Historical Volatility 114.01%
  • IV Percentile 91%
  • IV Rank 61.68%
  • IV High 151.49% on 01/17/23
  • IV Low 66.80% on 12/16/22
  • Put/Call Vol Ratio 0.21
  • Today's Volume 6,009
  • Volume Avg (30-Day) 8,347
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 91,453
  • Open Int (30-Day) 135,962

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.27
  • Number of Estimates 4
  • High Estimate -0.25
  • Low Estimate -0.28
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -8.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.07 +126.29%
on 12/28/22
9.55 -3.56%
on 01/13/23
+4.68 (+103.31%)
since 12/23/22
3-Month
4.07 +126.29%
on 12/28/22
9.55 -3.56%
on 01/13/23
+1.59 (+20.87%)
since 10/26/22
52-Week
4.07 +126.29%
on 12/28/22
20.48 -55.02%
on 02/16/22
-6.24 (-40.39%)
since 01/26/22

Most Recent Stories

More News
Aurinia Announces PTAB Has Terminated Inter Partes Review

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States’ Patent and Trademark Office has terminated the Inter Partes Review...

AUPH : 9.21 (+1.77%)
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has allowed a method of use patent application titled IMPROVED...

AUPH : 9.21 (+1.77%)
Why Shares of Aurinia Pharmaceuticals Soared This Week

A patent settlement and improved financials sent the stock soaring.

AUPH : 9.21 (+1.77%)
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its business performance. Preliminary unaudited net revenue for the three months and full year ended December...

AUPH : 9.21 (+1.77%)
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, is scheduled to present at the 41 st Annual J.P. Morgan...

AUPH : 9.21 (+1.77%)
Aurinia (AUPH) Soars 37.5%: Is Further Upside Left in the Stock?

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....

AUPH : 9.21 (+1.77%)
IMGN : 4.71 (-1.67%)
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that the Company’s...

AUPH : 9.21 (+1.77%)
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announces it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd.,...

AUPH : 9.21 (+1.77%)
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that the Company’s...

AUPH : 9.21 (+1.77%)
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced that the...

AUPH : 9.21 (+1.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

3rd Resistance Point 9.71
2nd Resistance Point 9.51
1st Resistance Point 9.36
Last Price 9.21
1st Support Level 9.01
2nd Support Level 8.80
3rd Support Level 8.65

See More

52-Week High 20.48
Fibonacci 61.8% 14.21
Fibonacci 50% 12.27
Fibonacci 38.2% 10.34
Last Price 9.21
52-Week Low 4.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar